AstraZeneca doesn’t lose late-stage trials often — which is exactly why Thursday landed so hard. The company said its heart drug Wainua, developed with California-based Ionis Pharmaceuticals, failed the primary goal of CARDIO-TTRansform, the Phase 3 study testing it in transthyretin amyloid cardiomyopathy, or ATTR-CM. Over 140 weeks, adding Wainua to standard care did not cut cardiovascular deaths or repeat heart events by a statistically significant margin versus placebo.
The drug is no failure everywhere: Wainua, an antisense “gene silencer” that lowers production of the misfolding TTR protein, has been approved since 2023 for a rarer nerve form of the disease. But ATTR-CM — a progressive, often fatal condition in which that same protein stiffens the heart muscle — was the far bigger prize. It just slipped away.
The tape was brutal, and lopsided. AstraZeneca, one of the world’s largest drugmakers with dozens of medicines, fell about 8% — a rare one-day gut-check for a stock that usually grinds higher on pipeline wins. Ionis, a fraction of the size and far more dependent on this single molecule, cratered roughly 20% for its worst session in more than five years. When a trial reads out binary, the smaller partner wears the bigger bruise.
Here’s the part that should worry latecomers everywhere: Wainua didn’t fail in an empty field. ATTR-CM already has three drugs at or near blockbuster sales — Pfizer’s tafamidis, BridgeBio’s acoramidis, and Alnylam’s Amvuttra, the first RNA-interference therapy cleared for the heart condition last year. AstraZeneca’s own statement carried the tell: most patients in the trial were already on a stabiliser drug. Beating placebo is one thing; beating placebo when the control group is already getting treatments that work is a much higher bar — and Wainua couldn’t clear it. On a day the broad market rallied, Alnylam, whose gene silencer does the job, was the standout winner.
Our take: This is what a crowded market does to a follow-on drug. The trial wasn’t really Wainua versus nothing — it was Wainua versus a standard of care that has quietly gotten good. AstraZeneca can absorb the miss; it has one of the deepest pipelines in the industry and will keep selling Wainua for the nerve indication. Ionis can’t shrug it off as easily, which is why its stock took the full hit. The broader lesson for anyone holding a single-catalyst biotech: the downside of a binary trial doesn’t care how big the addressable market looked on the slide deck.
What to watch
- ESC Congress, August. The full CARDIO-TTRansform data lands at the European Society of Cardiology meeting. AstraZeneca flagged a subgroup signal it wants to detail — watch whether it’s enough to support a narrower filing.
- Was 20% an over-reaction? At least one analyst already argued Ionis’s drop overshot, given its broader pipeline and royalty streams. The bounce-back — or lack of one — will settle it.
- Alnylam’s share grab. With Wainua sidelined in cardiomyopathy, Amvuttra’s path to ATTR-CM leadership just got clearer. The next sales update is the scoreboard.
- AstraZeneca’s 2030 ambitions. Management has staked out aggressive revenue targets. One failed trial won’t break them — but the Street will ask how much of the growth story leaned on expanding Wainua.